Coversyl 8 - tablet Perindopril Erbumine - 8mg 30 Tablet(s) / Box Servier Bangladesh Operation Introduction: Coversyl 8 belongs to a group of medicines known as angiotensin converting enzyme (ACE) inhibitor. It is widely used to treat high blood pressure and heart failure and may be prescribed after a heart attack. It also lowers the chances of having a heart attack or stroke. Coversyl 8 can be prescribed either alone or in combination with other medicines. It should be taken on an empty stomach. This medicine should be taken at the same time each day to get the most benefit. It is important to continue taking it regularly even if you feel well or even if... Uses of Coversyl 8: Hypertension (high blood pressure)Prevention of heart attack and strokeHeart failure Side effects of Coversyl 8: Decreased blood pressureCoughIncreased potassium level in bloodFatigueWeaknessDizziness How to use Coversyl 8: Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it. Coversyl 8 is to be taken empty stomach. How Coversyl 8 works: Coversyl 8 is an angiotensin converting enzyme (ACE) inhibitor. It works by reducing stress on the heart and relaxing blood vessel so that blood flows more smoothly and the heart can pump blood more efficiently. What if you forget to take Coversyl 8?: If you miss a dose of Coversyl 8, skip it and continue with your normal schedule. Do not double the dose. Indication: Hypertension, IHD, Heart failure Administration: Should be taken on an empty stomach. Take before meals. Adult Dose: Oral Adult Hypertension 4-8 mg PO qDay or divided q12hr Maximum: 16 mg/day PO divided q12hr Stable Coronary Artery Disease (CAD) 4 mg PO qDay for 2 weeks, THEN increase as tolerated to 8 mg/day PO divided q12hr Reduce risk of cardiovascular mortality or MI in patients with stable CAD Heart Failure 2 mg PO qDay initially to maximum 8-16 mg PO qDay Elderly: Initially, 2 mg once daily. Dose may be increased to max 8 mg Renal Dose: Renal impairment: CrCl (ml/min) Dosage Recommendation <15 2 mg on dialysis days. 15-30 2 mg on alternate days. 30-60 2 mg Contraindication: History of angioedema related to previous ACE inhibitor treatment. Pregnancy (2nd/3rd trimesters). Mode of Action: Perindopril is an ACE inhibitor, which acts by inhibiting the conversion of angiotensin I to angiotensin II, reducing the activity of the sympathetic nervous system and inhibiting enzyme kininase, which is involved in the conversion of bradykinin and other substances. Precaution: History of airway surgery. Withdraw if there is significant increase in LFTs. Risk factors for hyperkalaemia; monitor potassium closely. Patients dependent on renin-angiotensin-aldosterone system; consider withdrawal in patients with progressive deterioration in renal function. Collagen vascular disease. Hypovolaemia; monitor BP with the 1st dose. Unilateral renal artery stenosis and pre-existing renal insufficiency; valvular aortic stenosis. Before, during, or immediately after anaesthesia. May impair ability to drive or operate machinery. Lactation. Lactation: not known if distributed into breast milk; use caution Side Effect: >10% Headache (23%),Cough (12%) 1-10% Dizziness (8%),Back pain (6%),Lower extremity pain (5%),Abnormal ECG (2%),Palpitation (1%),Depression (2%),Somnolence (1%),Menstrual disorder (1%),Edema (4%),ALT increased (2%),Sexual dysfunction (male 1%),Sleep disorder (3%),Chest pain (2%),Nausea/vomiting (2%),Flatulence (1%),Rash (2%),Hyperkalemia (1%),Tinnitus (2%) Frequency Not Defined Intestinal angioedema,Liver failure (rare),Leukopenia,Pruritus,Stroke,Syncope,Urinary retention,Vertigo,Amnesia Angioedema, More frequent in black patients (0.1%), Angioedema of lips, More frequent in black patients (0.1%), Angioedema of throat, More frequent in black patients (0.1%) Potentially Fatal: Anaphylactoid reactions, angioedema. Interaction: May enhance hypotensive effect w/ diuretics. Additive hyperkalaemic effect w/ K supplements, K-sparing diuretics, and other drugs (e.g. ciclosporin, heparin, indometacin). May increase serum levels and toxicity of lithium. Antihypertensive effect may be reduced by aspirin or other NSAIDs. Coadministration w/ NSAIDs may also increase the risk of renal impairment. Increased risk of hypoglycaemia w/ antidiabetic agents. Rarely, nitritoid reactions occur w/ concomitant use of gold (sodium aurothiomalate). Potentially Fatal: Increased risk of hypotension, hyperkalaemia and changes in renal function (including acute renal failure) w/ aliskiren in patients w/ diabetes or renal impairment.